JP Morgan Chase
SCMP

JP Morgan Chase’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

JP Morgan Chase’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-981,726
Closed -$17.6M – 5802
2017
Q4 		$17.6M Buy
+981,726
New +$12.1M ﹤0.01% 1674
2017
Q3 		– Sell
-11,141
Closed -$117K – 5351
2017
Q2 		$117K Buy
+11,141
New +$114K ﹤0.01% 4126
2016
Q3 		– Sell
-31
Closed – – 4999
2016
Q2 		$0 Hold
31
– – ﹤0.01% 5116
2016
Q1 		$0 Buy
+31
New +$392 ﹤0.01% 5118

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

JP Morgan Chase's SCMP Position: Q1 2018 in Review

JP Morgan Chase sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 981,726 shares — an estimated $17.6M sold.

JP Morgan Chase first reported a position in SCMP in Q1 2016 and held it in 4 quarters. The position peaked at $17.6M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • JP Morgan Chase reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Chase sold 981,726 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $17.6M.
  • JP Morgan Chase first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
  • JP Morgan Chase's Sucampo Pharmaceuticals, Inc. position peaked at $17.6M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.